Fa. Vicini et al., TREATMENT OPTIONS FOR LOCALIZED PROSTATE-CANCER BASED ON PRETREATMENTSERUM PROSTATE-SPECIFIC ANTIGEN LEVELS, The Journal of urology, 158(2), 1997, pp. 319-325
Purpose: We reviewed all available literature on early stage prostate
cancer treatment in which pretreatment serum prostate specific antigen
(PSA) levels were used to stratify patients. We determined if any con
clusions could be reached regarding the optimal therapy of this diseas
e. Materials and Methods: A MEDLINE search was conducted to obtain all
articles in English on prostate cancer treatment from 1986 to 1996 in
which PSA levels were used to stratify patients and evaluate outcome,
Studies were considered eligible only if they met all criteria of pre
treatment PSA values recorded and grouped for subsequent evaluation, p
osttreatment PSA values monitored continuously, definitions of biochem
ical control stated and median followup given. Results: Of the 16 surg
ical studies identified only 3 met the inclusion criteria, Of the 30 r
adiation therapy articles identified 15 met the inclusion criteria, in
cluding 2 on conformal external beam radiotherapy, 8 on conventional e
xternal beam radiotherapy and 5 on interstitial brachytherapy. No stud
ies using neutrons or combined hormonal therapy with surgery or radiot
herapy were identified in which patients were stratified by pretreatme
nt PSA. Results for all therapies were extremely variable with the 3 t
o 5-year rates of biochemical control ranging from 48 to 100% for pati
ents with a pretreatment PSA of less than 4 ng./ml., 44 to 90% for PSA
more than 4 to 10 ng./ml. and 27 to 89% for PSA more than 10 to 20 ng
./ml, Even using the same treatment modality, a wide range of results
were obtained, No treatment option consistently produced superior resu
lts. Conclusions: When data were reviewed from studies using pretreatm
ent serum PSA to stratify patients, no consistently superior treatment
option in the radiotherapy or surgical literature emerged. These data
suggest that standard definitions of disease stage and biochemical cu
re must be adopted to evaluate treatment efficacy and advise patients
on the most appropriate treatment option for the disease.